509 related articles for article (PubMed ID: 28097882)
1. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
Cheng JWM; Badreldin HA; Patel DK; Bhatt SH
Curr Med Res Opin; 2017 Jun; 33(6):985-992. PubMed ID: 28097882
[TBL] [Abstract][Full Text] [Related]
2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
3. Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?
Cheng JWM; Colucci VJ; Kalus JS; Spinler SA
Ann Pharmacother; 2019 May; 53(5):510-522. PubMed ID: 30516068
[TBL] [Abstract][Full Text] [Related]
4. Drugs for type 2 diabetes.
Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
[No Abstract] [Full Text] [Related]
5. Cardiovascular safety outcomes of new antidiabetic therapies.
LeBras MH; Barry AR; Koshman SL
Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
[TBL] [Abstract][Full Text] [Related]
6. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
[TBL] [Abstract][Full Text] [Related]
7. Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.
Chawla H; Tandon N
Am J Cardiovasc Drugs; 2017 Jun; 17(3):203-215. PubMed ID: 28197977
[TBL] [Abstract][Full Text] [Related]
8. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
Bailey CJ; Marx N
Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
[TBL] [Abstract][Full Text] [Related]
10. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Protection with Anti-hyperglycemic Agents.
Deedwania P; Acharya T
Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
13. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcome trials of glucose-lowering medications: an update.
Home P
Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
[TBL] [Abstract][Full Text] [Related]
15. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
16. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS; Zheng YD; Yuan Y; Chen SC; Xie BC
Front Endocrinol (Lausanne); 2021; 12():735824. PubMed ID: 34721294
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.
Saulsberry WJ; Coleman CI; Mearns ES; Zaccaro E; Doleh Y; Sobieraj DM
Int J Clin Pract; 2015 Nov; 69(11):1221-35. PubMed ID: 26215321
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
Giugliano D; Maiorino MI; Bellastella G; Esposito K
Endocrine; 2018 May; 60(2):224-228. PubMed ID: 28895030
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Lim S; Eckel RH; Koh KK
Atherosclerosis; 2018 May; 272():33-40. PubMed ID: 29547706
[TBL] [Abstract][Full Text] [Related]
20. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
